UK’s NICE Publishes Briefing Supporting PredictImmune Tool for Estimating IBD Flare-up Likelihood

UK’s NICE Publishes Briefing Supporting PredictImmune Tool for Estimating IBD Flare-up Likelihood
The National Institute for Health and Care Excellence (NICE) supports the use of PredictImmune's newly launched prognostic tool, PredictSURE IBD, for estimating the likelihoood of disease flare-ups in patients with inflammatory bowel disease (IBD), according to a published Medtech Innovation Briefing (MIB). PredictSURE IBD is a prognostic tool that estimates the chances of disease flare-ups in patients recently diagnosed with Crohn's disease or ulcerative colitis. It also will help physicians decide the best course of treatment for these patients. The tool was launched April 2 through Cambridge University Hospitals NHS Foundation Trust, and will be available to IBD patients in the United Kingdom and Ireland, according to a press release from PredictImmune. "It enables both clinicians and patients to understand, at the point of diagnosis, the likely course of disease — differentiating between an aggressive or milder form of the disease — and opens up the possibility of better treatment choices from the outset," the release states. PredictSURE IBD works by looking for specific genetic signatures using a technique called quantitative real-time polymerase chain reaction (qPCR). Clinical findings, summarized in the MIB report, demonstrate that PredictSURE IBD can accurately estimate the probability that a patient with IBD will experience a severe relapse episode. Results also indicate that starting treatment with tumor necrosis factor (TNF) inhibitors, such as Remicade (infliximab) or Humira (adalimumab) shortly after patients are diagnosed may improve the disease outcomes. TNF is a pro-inflammatory cytokine — a molecule that mediates and regulates immune and inflammatory response — that is often found at abnormally high levels in patients with IBD.
Subscribe or to access all post and page content.